Knockdown of PSMD1 or PSMD3 reduced NF-κB protein expression and transcriptional activity in CML cells that are both sensitive and resistant to imatinib. Here, PSMD3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.